Related Experiment Videos
[Influence of cefroxadine dry syrup on intestinal bacterial flora]
Abstract:
Influence of cefroxadine (CXD) dry syrup on intestinal bacterial flora was studied in mice infected with 4 species of bacteria, namely, Escherichia coli, Enterococcus faecalis, Bacteroides fragilis and Bifidobacterium breve, and in pediatric patients having infections in the respiratory tract and cutaneous/soft tissues. The results were summarized as follows: CXD dry syrup was administered for 5 consecutive days to mice infected with the 4 species. No considerable changes were observed in levels of bacteria in the feces and in different parts of digestive tracts. Eleven pediatric patients were orally administered with 30-54 mg/kg of CXD dry syrup a day for 7-15 consecutive days. Symptom of diarrhea was noted in 2 patients. Dominant species of the intestinal flora such as E. coli, Bifidobacterium, and Bacteroides sometimes decreased in patients treated with CXD dry syrup. In general, however, decreases in numbers of these bacteria were insignificant. Changes of intestinal flora in patients treated with CXD dry syrup were apparently smaller than those treated with ampicillin and were similar to those treated with cephalexin or amoxicillin.
Insights
Cefroxadine dry syrup showed minimal impact on intestinal bacterial flora in mice and pediatric patients. While some minor decreases in gut bacteria were observed in children, the changes were insignificant compared to other antibiotics.
Area of Science:
- Microbiology
- Pharmacology
- Pediatrics
Background:
- Intestinal bacterial flora plays a crucial role in maintaining host health.
- Antibiotic use can significantly alter the composition of the gut microbiome.
- Understanding the impact of cefroxadine (CXD) on intestinal flora is important for its clinical application.
Purpose of the Study:
- To investigate the influence of cefroxadine (CXD) dry syrup on intestinal bacterial flora.
- To compare the effects of CXD on gut bacteria in infected mice and pediatric patients.
Main Methods:
- Mice infected with Escherichia coli, Enterococcus faecalis, Bacteroides fragilis, and Bifidobacterium breve were administered CXD dry syrup for 5 days.
- Pediatric patients with respiratory tract and cutaneous/soft tissue infections received oral CXD dry syrup (30-54 mg/kg/day) for 7-15 days.
- Fecal and digestive tract bacterial levels were analyzed in mice; intestinal flora composition was assessed in pediatric patients.
Main Results:
- No considerable changes in bacterial levels were observed in mice across fecal and digestive tract samples.
- Two out of eleven pediatric patients experienced diarrhea.
- While dominant intestinal flora species like E. coli, Bifidobacterium, and Bacteroides sometimes decreased in patients, these changes were generally insignificant.
- The alterations in intestinal flora caused by CXD were less pronounced than those seen with ampicillin and comparable to cephalexin or amoxicillin.
Conclusions:
- Cefroxadine dry syrup exhibits a limited impact on intestinal bacterial flora in both murine models and pediatric patients.
- The observed changes in gut microbiota composition are generally minor and transient.
- CXD appears to have a favorable safety profile regarding intestinal flora disruption compared to certain other antibiotics.